VRPX News and Press, Virpax Pharmaceuticals Inc. From 03/05/25

VRPX - Virpax's NES100 to be Presented at The Society of Toxicology by NCATS

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pl...

VRPX - Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, would...

VRPX - Virpax Reports Positive Probudur Results with US Army for Combat Care Study

2025-02-14 08:25:04 ET DENVER, Colo., Feb 14, 2025 ( 247marketnews.com )- Virpax Pharmaceuticals (NASDAQ: VRPX ) completed a full study following the initial Probudur pilot study conducted by the U.S. Army Institute of Surgical Research (USAISR), under a Cooperative Research and...

VRPX - Virpax Confirms Positive Results with US Army with Probudur(TM) for Combat Care Study

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today...

VRPX - Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pl...

VRPX - Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering

NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) in the successful close of its $6 million f...

VRPX - Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 mil...

VRPX - Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $0.20 of...

Company Name:	Virpax Pharmaceuticals Inc.
Stock Symbol:	VRPX
Market:	NASDAQ
Website:	virpaxpharma.com